Hexarelin dosage

Protocol

1. 1

   Reconstitute the vial

   A typical 5 mg vial reconstituted with 2 mL bacteriostatic water gives 2.5 mg/mL (2500 mcg/mL). A 100 mcg dose equals 4 units on a U100 insulin syringe.

   Open tool →
2. 2

   Measure the dose

   Typical Hexarelin dose is 0.1 mg (100 to 200 mcg per injection, 1 to 2 times daily. Doses above 200 mcg produce larger pulses but faster tachyphylaxis.). Use a weight-based calculator for individual adjustments.

   Open tool →
3. 3

   Set the frequency

   Administer 1-2x daily. Half-life of 1 hours anchors the dosing interval.

   Open tool →
4. 4

   Cycle if needed

   2 to 4 week pulses with extended off-periods; longer continuous use loses efficacy due to tachyphylaxis.

   Open tool →
5. 5

   Monitor for side effects

   Watch for: water retention; vivid dreams; head pressure or flushing; transient lethargy. Stop or reduce dose if tolerability breaks down.

Why this dose

Hexapeptide agonist of GHS-R1a producing acute GH release with cortisol and prolactin co-elevation. Independent CD36 binding produces GH-independent cardioprotective signaling in preclinical models.

The typical dose (0.1 mg) reflects 100 to 200 mcg per injection, 1 to 2 times daily. Doses above 200 mcg produce larger pulses but faster tachyphylaxis.. Individual response varies with body weight, baseline status, concurrent training, and concurrent medications, so the labeled range is the starting point rather than the prescription.

How to administer

Hexarelin is administered via the subcutaneous, intranasal, intravenous routes. Subcutaneous injection into rotated abdominal sites is the standard self-administration approach for peptide protocols; rotate sites to limit local irritation. Use a fresh insulin syringe per dose. Intranasal delivery uses a metered spray; tilt the head slightly forward and breathe gently while spraying.

Onset of action runs around 15 minutes after administration. Peak effect lands near 30 minutes post-dose. Plan the administration window so that peak effect lines up with whatever outcome you are dosing for, whether that is training, sleep, or symptom coverage.

Half-life note: Plasma half-life ~30 to 60 minutes. Acute GH peak within 15 to 30 minutes returns to baseline within 2 to 3 hours.

Cycling and tolerance

2 to 4 week pulses with extended off-periods; longer continuous use loses efficacy due to tachyphylaxis.

The cycling rationale for receptor-active compounds is partly empirical and partly mechanistic: continuous high-dose stimulation can downregulate target receptors or accelerate negative-feedback loops on endogenous production. Built-in off-periods give the system time to resensitize before the next phase, which preserves the effective dose-response over a longer arc.

Effects to expect at typical dose

• Synthetic hexapeptide GHS-R1a agonist; produces the largest acute GH pulse of the synthetic GHRP class
• Independent CD36 signaling produces cardioprotective effects in rodent ischemia models, GH-independent
• Pronounced tachyphylaxis: GH response attenuates over 2 to 4 weeks of daily dosing
• More cortisol and prolactin elevation than GHRP-2 or ipamorelin
• Anecdotal protocols use 100 to 200 mcg subcutaneously 1 to 2 times daily for 2 to 4 week pulses
• Banned by WADA under S2; advanced through phase 2 trials but never reached registration

Side effects and interactions

Common side effects

• water retention
• vivid dreams
• head pressure or flushing
• transient lethargy
• tingling at injection site

Notable interactions

• insulin (moderate): sustained GH can blunt insulin sensitivity over weeks
• corticosteroids (moderate): amplify cortisol load; blunt GH response
• CJC-1295 (minor): synergistic GH release; accelerates tachyphylaxis if used continuously
• sermorelin (minor): additive GH release via parallel GHRH and ghrelin pathways

Lists above cover commonly reported and well-characterized items. They are not exhaustive: review the full Hexarelin profile and discuss with a clinician familiar with your medication list before starting, particularly if you are on prescription therapy or have a chronic condition.

Regulatory snapshot

WADA status

banned

DEA / Rx

Not scheduled (research chemical)

Pregnancy

Insufficient data; not recommended

Legal status

Not FDA approved; advanced through phase 2 trials in EU but never registered; research-use-only grey market; banned by WADA

Do not use if

• pregnancy
• active malignancy
• history of pituitary tumor
• uncontrolled diabetes
• prolactin-sensitive states

Related research